Comparative Pharmacology
Head-to-head clinical analysis: BRINZOLAMIDE versus DICHLORPHENAMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRINZOLAMIDE versus DICHLORPHENAMIDE.
BRINZOLAMIDE vs DICHLORPHENAMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Brinzolamide is a carbonic anhydrase inhibitor. It inhibits carbonic anhydrase II (CA-II) in the ciliary processes of the eye, reducing aqueous humor secretion and thereby lowering intraocular pressure.
Dichlorphenamide is a carbonic anhydrase inhibitor. It inhibits the enzyme carbonic anhydrase in the proximal renal tubule, reducing reabsorption of bicarbonate, leading to metabolic acidosis, and decreasing intraocular pressure by reducing aqueous humor formation.
1 drop of 1% solution in the affected eye(s) twice daily.
25-50 mg orally twice daily.
None Documented
None Documented
Terminal elimination half-life: 111 days (due to extensive red blood cell binding); clinical context: steady-state reached after 8–12 weeks of dosing
Clinical Note
moderateBrinzolamide + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Brinzolamide."
Clinical Note
moderateBrinzolamide + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Brinzolamide."
Clinical Note
moderateBrinzolamide + Cyclosporine
"The metabolism of Cyclosporine can be decreased when combined with Brinzolamide."
Clinical Note
moderateBrinzolamide + Fluconazole
Terminal elimination half-life of 2-4 hours; increased in renal impairment, up to 12-24 hours in severe insufficiency.
Renal: approximately 60% unchanged; biliary/fecal: minimal (<10%)
Primarily renal via tubular secretion; 50-70% excreted unchanged in urine; minor biliary/fecal elimination (<20%).
Category A/B
Category C
Carbonic Anhydrase Inhibitor
Carbonic Anhydrase Inhibitor
"The metabolism of Fluconazole can be decreased when combined with Brinzolamide."